Back to today’s briefing

Story perspectives

Omalizumab Outperforms Oral Therapy in Food Allergy Treatment

3/4/2025

49 5

Summary

Story summary

A groundbreaking study reveals that omalizumab, known as Xolair, outshines oral immunotherapy in treating multiple food allergies. Remarkably, 36% of participants on omalizumab could tolerate substantial allergen amounts, versus just 19% on oral therapy. With fewer side effects, omalizumab emerges as a hopeful new option for those battling food allergies.

1 of 1

Story summary

A groundbreaking study reveals that omalizumab, known as Xolair, outshines oral immunotherapy in treating multiple food allergies. Remarkably, 36% of participants on omalizumab could tolerate substantial allergen amounts, versus just 19% on oral therapy. With fewer side effects, omalizumab emerges as a hopeful new option for those battling food allergies.